Marco Lanzillotta
Vita-Salute San Raffaele University
EpidemiologyInternal medicinePathologyCD20RheumatologyNaive B cellCohort studyImmunologyBiopsyAutoimmune pancreatitisB cellCD19DiseaseIgG4-related diseaseFibrosisRituximabDifferential diagnosisGlucocorticoidMethotrexateCancer researchMedicineCohortGastroenterology
60Publications
16H-index
912Citations
Publications 59
Newest
#1Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 27
#2Emanuele Bozzalla-Cassione (UniSR: Vita-Salute San Raffaele University)H-Index: 3
Last. Angelo A. Manfredi (UniSR: Vita-Salute San Raffaele University)H-Index: 77
view all 19 authors...
OBJECTIVE: An unconventional population of CD4+ signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxic effector memory T (TEM ) cells (CD4+ cytotoxic T lymphocytes [CTLs]) has been linked causally to IgG4-related disease (IgG4-RD). Glucocorticoids represent the first-line therapeutic approach in patients with IgG4-RD, but their mechanism of action in this specific condition remains unknown. We undertook this study to determine the impact of glucocorticoids on CD4+...
40 CitationsSource
Source
#1Marco LanzillottaH-Index: 16
#2E. Della TorreH-Index: 2
Last. Lorenzo DagnaH-Index: 37
view all 9 authors...
Background IgG4-related disease (IgG4-RD) is relapsing-remitting systemic fibro-inflammatory condition characterised by elevated serum IgG4 concentration and by tumor-like lesions[.1 Glucocorticoids represent the treatment of choice to induce IgG4-RD remission but relapses occur in almost 50% of patients at two years.2 Several evidences suggest that B cells are central to the pathogenesis of IgG4-RD, the most significant being (i) the clinical improvement induced by B-cell depletion with rituxim...
Source
#1Lucrezia Rovati (UniSR: Vita-Salute San Raffaele University)H-Index: 6
#2E. Della Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 2
Last. Angelo A. Manfredi (UniSR: Vita-Salute San Raffaele University)H-Index: 77
view all 9 authors...
Background IgG4-Related Disease (IgG4-RD) is a multi-organ fibro-inflammatory disorder characterised by tumefactive lesions with well-defined histological features including lymphoplasmacitic infiltrate rich in IgG4 + plasma cells, storiform fibrosis and obliterative phlebitis 1 . Alternatively-activated macrophages (M2) have also been reported to abundantly infiltrate IgG4-RD lesions, but their role in IgG4-RD pathogenesis remains elusive. M2 macrophages have been recently shown to modulate inn...
Source
#1E. Della Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 2
#2E. Bozzalla Cassione (UniSR: Vita-Salute San Raffaele University)H-Index: 2
Last. Angelo A. Manfredi (UniSR: Vita-Salute San Raffaele University)H-Index: 77
view all 12 authors...
Background IgG4-Related Disease (IgG4-RD) is a fibro-inflammatory disorder characterised by tumefactive lesions, frequent elevation of serum IgG4 levels, and tissue fibrosis.1 Glucocorticoids represent the treatment of choice to induce IgG4-RD remission but their effect on the cells orchestrating the disease remains unknown.1 We recently describerd an unconventional population of clonally expanded CD4+SLAMF7+ cytotoxic T effector memory (TEM) cells (CD4+CTLs) and causally linked it to IgG4-RD in...
Source
Intrathecal administration of rituximab—an anti-CD20 monoclonal antibody—is emerging as a promising therapeutic strategy for B cell lymphomas of the central nervous system (CNS).1 2 The rationale for administering rituximab directly into the cerebrospinal fluid (CSF) stems from the need to achieve optimal therapeutic concentrations within the intrathecal compartment. Rituximab, in fact, has a high molecular weight and only 0.1%–0.5% of its plasmatic concentrations crosses the ‘blood-brain barrie...
23 CitationsSource
#1Alvise Berti (UniSR: Vita-Salute San Raffaele University)H-Index: 17
#2Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 27
Last. Lorenzo Dagna (UniSR: Vita-Salute San Raffaele University)H-Index: 37
view all 17 authors...
Objective: [18F]Fluorodeoxyglucose (18F-FDG) PET/CT is increasingly used to assess organ involvement and response to treatment in IgG4-related disease (IgG4-RD), but clear correlations between 18F-FDG uptake and disease activity have not been established yet. We aimed to correlate the intensity and distribution of 18F-FDG uptake with validated clinical, serological and immunological parameters of IgG4-RD activity. Methods: Twenty patients with active IgG4-RD underwent a baseline 18F-FDG PET/CT. ...
36 CitationsSource
#1Marco Lanzillotta (UniSR: Vita-Salute San Raffaele University)H-Index: 16
#2Corrado Campochiaro (UniSR: Vita-Salute San Raffaele University)H-Index: 23
Last. Emanuel Della-Torre (UniSR: Vita-Salute San Raffaele University)H-Index: 27
view all 13 authors...
AbstractObjective: A series of destructive and tumefactive lesions of the midline structures have been recently added to the spectrum of IgG4-related disease (IgG4-RD). We examined the clinical, serological, endoscopic, radiological, and histological features that might be of utility in distinguishing IgG4-RD from other forms of inflammatory conditions with the potential to involve the sinonasal area and the oral cavity.Methods: We studied 11 consecutive patients with erosive and/or tumefactive ...
21 CitationsSource
#1Marco LanzillottaH-Index: 16
#2E. Della TorreH-Index: 2
Last. Lorenzo DagnaH-Index: 37
view all 8 authors...
Background IgG4-related disease (IgG4-RD) is a systemic fibro- inflammatory disorder characterized by fibrotic lesions infiltrated by IgG4 positive plasma cells (1). The prompt clinical responses obtained after B cell depletion with rituximab in IgG4-RD patients suggest that B lymphocytes drive the pathogenesis of this condition and sustain disease activity (2). This conclusion, however, requires further confirmation because IgG4-RD responds also to non-B cell depleting therapies such as glucoco...
Source
Background Medium to high dose glucocorticoids represents the treatment of choice for inducing remission in IgG4-related disease (IgG4-RD) patients1. However, clinicians might prefer alternative equally effective drugs in clinical settings where long-term corticosteroids treatment is contraindicated, such as diabetes or osteoporosis. We recently reported the efficacy of methotrexate in maintaining glucocorticoids induced IgG4-RD remission2. Objectives To evaluate the efficacy of methotrexate as ...
Source